This contract expires in 258 days (Dec 31, 2026).

Browse related active opportunities

FIRM FIXED PRICENO SET ASIDE USED.

AURAVAX THERAPEUTICS, INC. - THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN

PIID: 75A50124C00054Solicitation ID: 22-100-SOL-00003
Signed Date: Dec 19, 2025Effective Date: Sep 23, 2024End Date: Closes in 258 days

Key Details

Dollars Obligated
$749,999
Base & All Options
Awarding Sub-Agency
Office of Assistant Secretary for Preparedness and Response
Product Service Code
AN14 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; R&D ADMINISTRATIVE EXPENSES
Extent Competed
FULL AND OPEN COMPETITION
Number of Offers
1
Place of Performance
HOUSTON, TX, 770097431, CD-TX-18

Description

THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ASSESS THE ABILITY OF AURAVAX THERAPEUTICS? (AURAVAX) NOVEL MUCOSAL ADJUVANT NANOSTING-002, TOGETHER WITH INFLUENZA LIVE ATTENUATED VIRUS (LAV) CREATED WITH CODAGENIX NOVEL SYNTHETIC ATTENUATED VIRUS ENGIN

Contractor Information

UEI: PAN3ZK2YLAL2
CAGE Code: 969E2
Location: HOUSTON, TX
View Full Record on USASpending.gov

Stay Updated

Get notified about new opportunities matching your interests.

Related